



HHS Public Access

Author manuscript

Radiother Oncol. Author manuscript; available in PMC 2023 February 01.

Published in final edited form as:

Radiother Oncol. 2022 February ; 167: 143–148. doi:10.1016/j.radonc.2021.12.030.

Platelet glycoprotein Iba provides radiation protection

Adam Corken¹, Sanchita P. Ghosh³, Ruofei Du⁴, Marjan Boerma², Jerry Ware¹, Rupak Pathak^{2,*}

¹Department of Physiology and Biophysics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA

²Division of Radiation Health, Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA

³Armed Forces Radiobiology Research Institute, USUHS, Bethesda, MD 20814, USA

⁴Department of Biostatistics, College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Abstract

Background and Purpose: Platelet membrane glycoprotein Iba (GPIba), the major ligand-binding subunit of the GPIb-IX-V complex, binds to a number of ligands contributing to hemostasis, thrombosis, and inflammation. Binding to von Willebrand factor (VWF) initiates the process of hemostasis/thrombosis, while binding to the leukocyte receptor Macrophage-1 antigen (Mac-1) has been implicated in modulating the inflammatory response. Thus as GPIba resides at the nexus of thrombosis and inflammation, we investigated the impact of GPIba on radiation injury outcomes as this injury triggers both the thrombotic and inflammatory pathways.

Materials and Methods: We used wild-type (WT) C57BL/6J mice and a dysfunctional GPIba mouse model, in which endogenous GPIba is replaced with a non-functional α -subunit (hIL-4R/Iba), to determine whether the impairment of platelet GPIba alters radiation response. Following exposure to 8.5 Gy total body irradiation (TBI), a series of parameters including radiation lethality, platelet-neutrophil/monocyte interactions, neutrophil/monocyte activation, serum cytokine levels and intestinal injury, were compared between the strains.

Results: The lack of functional GPIba resulted in higher radiation lethality, greater monocyte activation, increased levels of serum pro-inflammatory cytokines, heightened intestinal damage, and a reduction of intestinal neutrophil recovery.

Conclusion: These data suggest that loss of platelet GPIba enhances radiation toxicity and that GPIba-mediated interactions may play a crucial role in limiting radiation damage. Thus,

* **Correspondence to:** Rupak Pathak, PhD, Division of Radiation Health, University of Arkansas for Medical Sciences, 4301 West Markham, Little Rock, AR 72205, USA. rpathak@uams.edu, Telephone: +1-5016861472.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interest
None

a mechanistic understanding of the biological impact of GPIb α following TBI could provide crucial insights for improving the safety of radiotherapy and minimizing the deleterious effects of accidental or occupational exposure to high-dose radiation.

Keywords

Platelets; Radiation; Inflammation; Intestines; Leukocytes

INTRODUCTION

Radiation toxicity within healthy tissue results from radiotherapy. Within minutes, radiation elicits apoptosis or mitotic death in blood cells and the epithelium of the intestinal mucosa.^{1,3} This triggers the loss of intestinal integrity which increases the risk of intestinal flora dissemination, in turn causing inflammation and enhancing the likelihood of sepsis.⁴ Additionally, radiation can activate platelets and leukocytes (neutrophils and monocytes) which causes the secretion of pro-inflammatory cytokines,⁵ thereby exacerbating inflammation. Persistent inflammation, resulting from radiation injury, can also promote thrombosis (pathological clot formation) which itself causes ischemia, hypoxia and tissue damage in addition to stimulating the inflammatory response thus forming a vicious cycle.⁸

Radiation elicits intestinal damage either directly or via the resulting inflammation it causes. Radiation exposure causes the loss of intestinal epithelial cells, resulting in shortened villi and reduced mucosal surface area (MSA), which compromises the intestinal barrier function.¹⁸ This loss of barrier integrity facilitates the stromal invasion by luminal bacteria of the intestine. Further migration into the circulation triggers an inflammatory response and the possibility of sepsis.⁴ Additionally, radiation exposure damages the intestinal crypts that harbor intestinal stem cells. Damage to the stem cell population adversely affect the regeneration of the mucosal epithelium, further exacerbating radiation induced intestinal damage.

Of note, platelets, the primary drivers of hemostasis, actively participate within the inflammatory pathway.⁹ Specifically, GPIb α , the ligand binding subunit of GPIb-IX-V complex, has been shown to bind leukocyte Mac-1 (α M β 2, CD11b/CD18)^{14,13,15} and exerts either a pro- or anti-inflammatory response depending on the model of inflammation. Previously, the induction of sepsis in GPIb α deficient mouse model demonstrated that the loss of the GPIb α /Mac-1 axis enhanced circulating levels of pro-inflammatory cytokines.¹⁷ Therefore, it is possible that GPIb α plays a similar role in minimizing the cytokine storm and other inflammatory consequences induced by radiation injury. Thus, the role of platelet GPIb α in modulating inflammation caused by radiation warrants investigation. Here we demonstrate that GPIb α disruption causes increased sensitivity to radiation-induced systemic inflammation, intestinal injury, and lethality.

MATERIALS AND METHODS

Mouse model, irradiation, tissue collection and euthanasia

Animal studies were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and approved by the Institutional Animal Care and Use Committee at the University of Arkansas for Medical Sciences (UAMS). Male mice age 8-12 weeks were utilized, as the estrous cycle alters radiation responsiveness. The hIL-4R/Iba mouse strain is described elsewhere.^{17,19}

Mice (not anesthetized) were placed in a custom-made, Plexiglas chamber and exposed to a single 8.5 Gy TBI dose in a Shepherd Mark I ¹³⁷Cs irradiator (model 25, J. L. Shepherd & Associates, San Fernando, CA, USA, 1 Gy/min). The chamber was placed on a turntable rotating at six rpm for uniform radiation dose distribution.

For non-terminal blood isolation, mice were anesthetized with isoflurane inhalation and blood was collected from the retro-orbital sinus. Platelet counts were determined with a Hemavet 950 (Drew Scientific, Waterbury CT).

For tissue harvesting mice were anesthetized with an intraperitoneal injection of a xylazine (10-12.5 mg/kg) and ketamine (80-100 mg/kg) (Henry Schein, Dublin, OH, USA). Blood was collected from the retro-orbital sinus and intestinal samples were isolated and fixed in methanol-Carnoy's solution. Mice were euthanized by CO₂ asphyxiation followed by cervical cord dislocation.

TPO administration

Recombinant mouse thrombopoietin (TPO) (R&D Systems, 488-TO-025/CF) was dissolved in sterile PBS. A single dose of TPO (20 µg/kg) in 100 µL PBS was administered by intraperitoneal injection, while control mice received the same volume of PBS.

Flow cytometry

Sample preparation for flow cytometry analysis has been described elsewhere.¹⁷

Cytokine measurement

A Bio Rad 23-plex multiplex kit was used to measure serum cytokine levels with a Luminex-200 dual-laser flow analyzer (Luminex Corp., Austin, TX, USA).

Epithelial mucosal measurements

Fixed intestinal tissues were embedded in paraffin and cut into sections, de-waxed, stained with hematoxylin, washed with diH₂O, stained with 1% eosin solution, dehydrated with alcohol, washed with xylene, and mounted with Permount™ media (Thermo Fisher Scientific, Grand Island, NY, USA).

Mucosal surface area (MSA) was measured via computerized cycloid count method from vertical sections as described elsewhere.²⁰ The images of hematoxylin and eosin (H&E) stained intestinal sections were superimposed onto a grid system containing cycloids (short

curved lines in a systematic pattern), and the number of intersections between the mucosal surface and cycloids was counted.

H&E stained sections were used to measure villus height and crypt depth using a computer-assisted image analysis platform (Image-Pro Premier, Rockville, MD, USA). Height was measured from the tip to the base of each villus, and crypt depth was measured from the base to the top opening.

Crypt survival was measured by the microcolony assay described by Withers and Elkind.²¹

Immunohistochemical staining for myeloperoxidase (MPO) of proximal segments of the jejunum was obtained 0, 4, and 8 days after TBI to determine intestinal neutrophil recovery. Sections were incubated with MPO primary antibody (Dako, Glostrup, Denmark), followed by an incubation with secondary antibody (Vector laboratories, Burlingame, CA, USA). Slides were then incubated with HRP avidin–biotin complex (Vector Laboratories) before incubation in DAB-HCl solution (Sigma-Aldrich, St. Louis, MO, USA) and 0.003% H₂O₂ in TBS (Cell Signaling Technology). MPO positive cells were quantified using Image-Pro Premier software (Media Cybernetics; Rockville, MD, USA).

Statistical analysis

Data were analyzed with Prism software (version 8.0; GraphPad, San Diego, CA), SAS (version 9.4) and R (version 4.0.2). Following irradiation, Kaplan-Meier estimates were generated to assess survival probabilities over time while Log-rank tests were used to compare survival curves. Platelet-leukocyte associations and CD11b expression were compared using a Student's t-test for the comparison of means. ANOVA was used for comparing multiple groups. A two-sided value of $p < 0.05$ was considered statistically significant.

RESULTS

As platelet GPIba is capable of modulating the inflammatory response,¹⁷ we hypothesized that GPIba dysfunction would alter radiation-induced inflammation and lethality.²² Quantification of platelets prior to radiation indicated a ~30% reduction in platelet counts for hIL-4R/Iba mice relative to WTs, consistent with previous accounts (Figure 1A).¹⁷ A single intraperitoneal administration of TPO raised hIL-4R/Iba platelet counts to those in WT at 5 days after administration (Figure 1B). WT mice, hIL-4R/Iba mice with prior TPO treatment, and hIL-4R/Iba without TPO treatment were exposed to 8.5 Gy TBI. The hIL-4R/Iba group exhibited 100% (without TPO) and 89% (with TPO) mortality whereas 50% of WT survived until the experimental conclusion (Figure 1C). Since both hIL-4R/Iba groups showed a significantly higher mortality rate than WT, our results suggest that dysfunctional GPIba, not the reduced platelet count, is responsible for higher radiation lethality in hIL-4R/Iba mice.

As TPO treatment did not affect radiation lethality, subsequent experiments with hIL-4R/Iba mice were performed without TPO treatment.

The GPIIb/IIIa/Mac-1 interface facilitates platelet-leukocyte interactions under both physiological and pathological states. We investigated if GPIIb/IIIa dysfunction affected platelet-leukocyte interactions before and after TBI. Prior to TBI, GPIIb/IIIa dysfunction reduced platelet binding to neutrophils and monocytes. Since TBI causes a drop in leukocyte counts, we investigated alterations in platelet-leukocyte interactions at 4 h and 24 h post-exposure. WT and hIL-4R/IIIa mice did not display any significant change in the percent of platelet-neutrophil interactions when compared to sham at 4 h and 24 h (Figure 2A) with WT samples maintaining higher aggregate levels throughout. Platelet-monocyte interactions were maintained at 4 h post-irradiation for both WT and hIL-4R/IIIa, with WT samples similarly having higher aggregate levels (Figure 2B). Interestingly, monocytes were undetectable at 24 h in both strains after TBI, suggesting monocytes are more susceptible to radiation toxicity than neutrophils. This indicates that GPIIb/IIIa disruption is responsible for reducing platelet binding to both neutrophils and monocytes before and after TBI.

Leukocyte activation causes an increase in Mac-1 surface expression; therefore Mac-1 is a marker of leukocyte activation.²³ We hypothesized that leukocyte activation/Mac-1 (CD11b) expression would increase following TBI. Though neutrophil activation was less in hIL-4R/IIIa mice before radiation, no difference was observed after exposure, as both strains displayed a reduction in CD11b expression at 4 and 24 h (Figure 3A). Similarly, monocyte activation dropped in WT samples 4 h following irradiation while activation increased at 4 h for hIL-4R/IIIa (Figure 3B). This suggests that GPIIb/IIIa is capable of diminishing monocyte activation following TBI but has no effect on neutrophils.

As monocytes are highly secretory, we hypothesized that pro-inflammatory cytokine levels would be higher in hIL-4R/IIIa serum as a result of the elevated monocyte activation following TBI. Previous reports indicated maximal serum cytokine levels 3-7 days following radiation so we subjected serum samples collected 4 days following TBI to a panel of 23 cytokines (full panel: Supplemental Figure 1). Among the results, numerous pro-inflammatory cytokines derived primarily from monocytes were increased in hIL-4R/IIIa mice compared to WT (Figure 4). While under control conditions interleukin (IL)-6, macrophage inflammatory protein (MIP)-1 β , and tumor necrosis factor (TNF)- α levels were lower in hIL-4R/IIIa mice compared to WT, at day 4 after TBI, these 3 cytokines were induced in the hIL-4R/IIIa mice to levels significantly higher than in the WT. Moreover, IL-10, keratinocyte chemoattractant (KC), and monocyte chemoattractant protein (MCP)-1 were induced by TBI in hIL-4R/IIIa mice but not in WT (Figure 4).

Higher level of plasma pro-inflammatory cytokines can disrupt homeostasis in various tissues by impairing endothelial barrier integrity. We observed TBI causes significantly higher impairment of endothelial barrier integrity in the lung and intestinal tissues of hIL-4R/IIIa mice compared to WT. However, we did not observe statistically significant differences in vascular permeability in spleen, kidney, and heart (methods and results presented in Supplemental Figure 2).

Intestinal mucosa epithelial cells are highly sensitive to damage via direct radiation and radiation induced inflammation.²⁴ Since hIL-4R/IIIa mice exhibit higher levels of pro-inflammatory cytokines, we hypothesized these mice would also exhibit heightened

intestinal damage following TBI. Prior to irradiation we noted the MSA was reduced in hIL-4R/Iba mice ($p = 0.001$) (Figure 5A) while 4 days following TBI resulted in a recession of the MSA for both strains. Additionally, we noted a decrease in villus height in hIL-4R/Iba mice, but not in WT (Figure 5B). Crypt depth in both the strains was also increased following TBI (Figure 5C). No difference in the number of surviving crypts was detected in either strain (Figure 5D). This suggests that certain aspects of mucosal damage after TBI are GPIba dependent.

Neutrophils promote inflammation resolution via the phagocytosis of cell debris accumulated at sites of mucosal wounds, which can be caused by TBI. Since we observed higher inflammation in hIL-4R/Iba mice, we hypothesized that neutrophil recovery in the intestine would be reduced. We found a significant reduction in the number of intestinal neutrophils at 4 and 8 days following TBI in hIL-4R/Iba mice when compared to WT (Figure 6).

DISCUSSION

Nearly 3.05 million American cancer survivors were treated with radiation in 2016.²⁷ Despite the critical nature of this therapy, there is a risk of injury to healthy tissue which exacerbates morbidity and mortality. Additionally, radiation stimulates inflammation which if unchecked can persist and likewise contribute to tissue damage. Considering the number of people at risk of radiation exposure, it is essential to understand the mechanism of radiation-induced injury of healthy tissues. Furthermore, evidence suggests that platelets not only regulate hemostasis/thrombosis but also actively participate in the inflammatory response due to their interactions with leukocytes.⁹ This positioning at the interface of inflammation warranted investigation into the potential of platelets to alter radiation-induced inflammation, tissue damage and mortality.

Platelet-neutrophil and platelet-monocytes aggregates correlate to inflammation and inflammatory disorders.^{28,29} Platelet GPIba and leukocyte Mac-1 are well-documented binding partners and promote the formation of platelet-leukocyte aggregates.^{14,17} Though well characterized, the GPIba/Mac-1 axis significance within radiation induced inflammation is unknown. While irradiation did not alter platelet-leukocyte aggregates in WT and hIL-4/Iba mice after irradiation, the percentage of aggregates remained reduced in GPIba dysfunctional mice at all-time points. Moreover, we observed a significant decrease in neutrophil activation (Mac-1) for both strains and in WT monocytes following TBI. Interestingly, hIL-4/Iba mice had increased monocyte activation post-irradiation indicating GPIba deficiency may contribute to heightened inflammation.

Monocytes secrete numerous pro-inflammatory cytokines that elicit systemic inflammation. Previous reports found septic hIL-4R/Iba mice had elevated serum cytokine levels which resulted from reduced platelet-monocyte associations.¹⁷ This suggests GPIba modulates systemic inflammation and as radiation elicits systemic inflammation, we predicted GPIba dysfunction potentially increases radiation induced inflammation. Indeed, we observed an increase in pro-inflammatory cytokines in hIL-4R/Iba mice relative to WT after TBI, indicating GPIba disruption enhances radiation-induced inflammation. In future studies,

we will address the hypothesis that the pro-inflammatory cytokines that are upregulated in irradiated hIL-4R/Iba mice may lead to leukocyte activation that contribute to tissue damage and thereby the increased radiation mortality seen in these mice.

These heightened levels of cytokines could contribute to the observed intestinal mucosal epithelium damage following TBI⁴; however, it is difficult to discern whether mucosal damage is a cause or consequence of elevated cytokine levels. Also, we did not observe strain-dependent changes in crypt depth and number of surviving crypts following TBI. This implies that the mucosal epithelial layer, but not the crypt region, is differentially affected by GPIba disruption. This region-specific variation in radiation damage could be due to differences in radiation sensitivity between two intestinal regions, as mucosal epithelial cells are more radiosensitive than crypt cells. Intestinal stromal neutrophils also play a crucial role in the inflammatory resolution.^{31,32,33} We observed a reduction in intestinal neutrophil recovery in hIL-4/Iba mice relative to WT after TBI, and this diminished rate of neutrophil recovery potentially contributes to greater intestinal damage. While further studies are required to ascertain the role of GPIba in modulating the extent of healthy tissue damage after irradiation, our evidence suggests a GPIba component to intestinal toxicity, which is a major contributor to radiation induced mortality. Future studies will address the relative contribution of each of the immunological and intestinal events to radiation lethality in this mouse model. Lastly, since hIL-4R/Iba mice show curtailed clot formation compared to WT, it will be important to assess the effects of TBI on thrombosis in this mouse model.

CONCLUSIONS

We demonstrated the significance of platelet GPIba in modifying the pathophysiological response to radiation. Utilizing a model of GPIba dysfunction we demonstrated that GPIba disruption causes a reduction in circulating platelet-leukocyte aggregates, enhanced monocyte activation, elevated serum cytokines, increased intestinal damage, reduced intestinal neutrophil recovery, and heightened mortality after TBI. As such, our study provides insight into a previously unexplored role for platelet GPIba in modulating radiation toxicity. These findings establish a foundation to develop platelet-centric strategies to limit damage to healthy tissues that arises from radiotherapy or accidental overexposures.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We would like to thank Ms. Gail Wagoner for maintaining the breeding colonies, Dr. Ratan Sadhukhan for TPO injection, blood cells count, and permeability assay; Ms. Shukla Biswas for cytokine analysis, and Dr. Sarita Garg for histomorphometry and immunohistochemistry. The opinions contained herein are the views of the authors and are not necessarily those of Armed Forces Radiobiology Research Institute, the Uniformed Services of the University of the Health Sciences, or the Department of Defense.

Funding

This study was supported by a Collaborative Research Grant from National Institute of General Medical Sciences (NIGMS) under grant number 2P20GM103429-19 (RP); an intramural Medical Research Endowment Grant from

University of Arkansas for Medical Sciences (RP); an Institutional Development Award (IDeA) from the NIGMS of the National Institutes of Health under grant numbers P20 GM109005 (RP and MB).

Nonstandard Abbreviations and Acronyms

CD	Cluster of differentiation
GP	Glycoprotein
IL	Interleukin
IR	Ionizing radiation
KC	Keratinocyte chemoattractant
Mac-1	Macrophage-1 antigen
MCP-1	Monocyte Chemoattractant Protein 1
MFI	Mean fluorescence intensity
MIP-1β	Macrophage inflammatory protein-1 β
MSA	Mucosal surface area
SEM	Standard error of the mean
TBI	Total body irradiation
TNFα	Tumor necrosis factor alpha
TPO	Thrombopoietin
VWF	von Willebrand factor
WT	Wild type

References

1. Barnett GC, West CML, Dunning AM, Elliott RM, Coles CE, Pharoah PDP, Burnet NG. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. *Nat Rev Cancer*. 2009;9:134–142. doi: 10.1038/nrc2587. [PubMed: 19148183]
2. Citrin DE, Mitchell JB. Mechanisms of Normal Tissue Injury From Irradiation. *Semin Radiat Oncol*. 2017;27:316–324. doi: 10.1016/j.semradonc.2017.04.001. [PubMed: 28865514]
3. Kim JH, Jenrow KA, Brown SL. Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials. *Radiat Oncol J*. 2014;32:103–115. doi: 10.3857/roj.2014.32.3.103. [PubMed: 25324981]
4. François A, Milliat F, Guipaud O, Benderitter M. Inflammation and immunity in radiation damage to the gut mucosa. *Biomed Res Int*. 2013;2013:123241. doi: 10.1155/2013/123241. [PubMed: 23586015]
5. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. *Biochim Biophys Acta*. 2014;1843:2563–2582. doi: 10.1016/j.bbamcr.2014.05.014. [PubMed: 24892271]
6. Passacuale G, Ferro A. Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation. *Br J Clin Pharmacol*. 2011;72:604–618. doi: 10.1111/j.1365-2125.2011.03906.x. [PubMed: 21223359]

7. Distler JHW, Pisetsky DS, Huber LC, Kalden JR, Gay S, Distler O. Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. *Arthritis Rheum*. 2005;52:3337–3348. doi: 10.1002/art.21350. [PubMed: 16255015]
8. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. *Circulation*. 2001; 103:1718–1720. doi: 10.1161/01.cir.103.13.1718. [PubMed: 11282900]
9. Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. *Blood*. 2015;126:582–588. doi: 10.1182/blood-2014-08-531582. [PubMed: 26109205]
10. Mouthon MA, van der Meeren A, Gaugler MH, Visser TP, Squiban C, Gourmelon P, Wagemaker G. Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation. *Int J Radiat Oncol Biol Phys*. 1999;43:867–875. doi: 10.1016/s0360-3016(98)00477-5. [PubMed: 10098443]
11. Yamaguchi M, Hirouchi T, Yokoyama K, Nishiyama A, Murakami S, Kashiwakura I. The thrombopoietin mimetic romiplostim leads to the complete rescue of mice exposed to lethal ionizing radiation. *Sci Rep*. 2018;8:10659. doi: 10.1038/s41598-018-29013-5. [PubMed: 30006622]
12. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. *Arterioscler Thromb Vasc Biol*. 2010;30:2357–2361. doi: 10.1161/ATVBAHA.110.207480. [PubMed: 21071701]
13. Wang Y, Gao H, Shi C, Erhardt PW, Pavlovsky A, A Soloviev D, Bledzka K, Ustinov V, Zhu L, Qin J, et al. Leukocyte integrin Mac-1 regulates thrombosis via interaction with platelet GPIIb α . *Nat Commun*. 2017;8:15559. doi: 10.1038/ncomms15559. [PubMed: 28555620]
14. Zago AC, Simon DI, Wang Y, Sakuma M, Chen Z, Croce K, Ustinov V, Shi C, Martinez Filho EE. The importance of the interaction between leukocyte integrin Mac-1 and platelet glycoprotein Ib α for leukocyte recruitment by platelets and for the inflammatory response to vascular injury. *Arq Bras Cardiol*. 2008;90:54–63. doi: 10.1590/s0066-782x2008000100009. [PubMed: 18317641]
15. Wang Y, Sakuma M, Chen Z, Ustinov V, Shi C, Croce K, Zago AC, Lopez J, Andre P, Plow E, et al. Leukocyte engagement of platelet glycoprotein Iba α via the integrin Mac-1 is critical for the biological response to vascular injury. *Circulation*. 2005;112:2993–3000. doi: 10.1161/CIRCULATIONAHA.105.571315. [PubMed: 16260637]
16. Schuhmann MK, Guthmann J, Stoll G, Nieswandt B, Kraft P, Kleinschnitz C. Blocking of platelet glycoprotein receptor Ib reduces "thrombo-inflammation" in mice with acute ischemic stroke. *J Neuroinflammation*. 2017;14:18. doi: 10.1186/s12974-017-0792-y. [PubMed: 28109273]
17. Corken A, Russell S, Dent J, Post SR, Ware J. Platelet glycoprotein Ib-IX as a regulator of systemic inflammation. *Arterioscler Thromb Vasc Biol*. 2014;34:996–1001. doi: 10.1161/ATVBAHA.113.303113. [PubMed: 24504734]
18. Somosy Z, Horváth G, Telbisz A, Réz G, Pálfi Z. Morphological aspects of ionizing radiation response of small intestine. *Micron*. 2002;33:167–178. doi: 10.1016/s0968-4328(01)00013-0. [PubMed: 11567886]
19. Kanaji T, Russell S, Ware J. Amelioration of the macrothrombocytopenia associated with the murine Bernard-Soulier syndrome. *Blood*. 2002;100:2102–2107. doi: 10.1182/blood-2002-03-0997. [PubMed: 12200373]
20. Langberg CW, Sauer T, Reitan JB, Hauer-Jensen M. Relationship between intestinal fibrosis and histopathologic and morphometric changes in consequential and late radiation enteropathy. *Acta Oncol*. 1996;35:81–87. doi: 10.3109/02841869609098484.
21. Withers HR, Elkind MM. Microcolony survival assay for cells of mouse intestinal mucosa exposed to radiation. *Int J Radiat Biol Relat Stud Phys Chem Med*. 1970;17:261–267. doi: 10.1080/09553007014550291. [PubMed: 4912514]
22. Bonaccio M, Di Castelnuovo A, Pounis G, de Curtis A, Costanzo S, Persichillo M, Cerletti C, Donati MB, de Gaetano G, Iacoviello L. A score of low-grade inflammation and risk of mortality: prospective findings from the Moli-sani study. *Haematologica*. 2016;101:1434–1441. doi: 10.3324/haematol.2016.144055. [PubMed: 27742767]
23. Ali H, Haribabu B, Richardson RM, Snyderman R. Mechanisms of inflammation and leukocyte activation. *Med Clin North Am*. 1997;81:1–28. doi: 10.1016/s0025-7125(05)70503-4. [PubMed: 9012753]

24. Peuhkuri K, Vapaatalo H, Korpela R. Even low-grade inflammation impacts on small intestinal function. *World J Gastroenterol*. 2010;16:1057–1062. doi: 10.3748/wjg.v16.i9.1057. [PubMed: 20205274]
25. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. *CA Cancer J Clin*. 2019;69:363–385. doi: 10.3322/caac.21565. [PubMed: 31184787]
26. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. *CA Cancer J Clin*. 2016;66:271–289. doi: 10.3322/caac.21349. [PubMed: 27253694]
27. Bryant AK, Banegas MP, Martinez ME, Mell LK, Murphy JD. Trends in Radiation Therapy among Cancer Survivors in the United States, 2000-2030. *Cancer Epidemiol Biomarkers Prev*. 2017;26:963–970. doi: 10.1158/1055-9965.EPI-16-1023. [PubMed: 28096199]
28. Arber N, Berliner S, Pras E, Arber L, Fishelson Z, Kahn Y, Bassat MB, Pinkhas J, Aronson M. Heterotypic leukocyte aggregation in the peripheral blood of patients with leukemia, inflammation and stress. *Nouv Rev Fr Hematol*. 1991;33:251–255. [PubMed: 1956762]
29. Finsterbusch M, Schrottmaier WC, Kral-Pointner JB, Salzmann M, Assinger A. Measuring and interpreting platelet-leukocyte aggregates. *Platelets*. 2018;29:677–685. doi: 10.1080/09537104.2018.1430358. [PubMed: 29461910]
30. Hirahashi J, Hishikawa K, Kaname S, Tsuboi N, Wang Y, Simon DI, Stavrakis G, Shimosawa T, Xiao L, Nagahama Y, et al. Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury. *Circulation*. 2009;120:1255–1265. doi: 10.1161/CIRCULATIONAHA.109.873695. [PubMed: 19752320]
31. Park JE, Barbul A. Understanding the role of immune regulation in wound healing. *Am J Surg*. 2004;187:11S–16S. doi: 10.1016/S0002-9610(03)00296-4. [PubMed: 15147986]
32. Ebaid H Neutrophil depletion in the early inflammatory phase delayed cutaneous wound healing in older rats: improvements due to the use of un-denatured camel whey protein. *Diagn Pathol*. 2014;9:46. doi: 10.1186/1746-1596-9-46. [PubMed: 24593823]
33. Nishio N, Okawa Y, Sakurai H, Isobe K-i. Neutrophil depletion delays wound repair in aged mice. *Age (Dordr)*. 2008;30:11–19. doi: 10.1007/s11357-007-9043-y. [PubMed: 19424869]
34. Larsen A, Reitan JB, Aase ST, Hauer-Jensen M. Long-term prognosis in patients with severe late radiation enteropathy: a prospective cohort study. *World J Gastroenterol*. 2007;13:3610–3613. doi: 10.3748/wjg.v13.i26.3610. [PubMed: 17659712]
35. Kountouras J, Zavos C. Recent advances in the management of radiation colitis. *World J Gastroenterol*. 2008;14:7289–7301. doi: 10.3748/wjg.14.7289. [PubMed: 19109862]
36. Goldberg PA, Nicholls RJ, Porter NH, Love S, Grimsey JE. Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure. *Eur J Cancer*. 1994;30A:1602–1606. doi: 10.1016/0959-8049(94)00312-s. [PubMed: 7530469]

Essentials

- Platelet glycoprotein Iba (GPIba) dysfunction enhances radiation lethality in mice.
- GPIba dysfunction reduces the formation of platelet-leukocyte aggregates prior to and following total-body irradiation.
- Reduced platelet association with monocytes correlates with increased monocyte activation following radiation.
- GPIba dysfunction increases serum cytokine levels and intestinal damage and decreases neutrophil recovery in the intestine in response to radiation exposure.




Figure 1. Platelet counts prior to TBI and radiation lethality following TBI.

(A) Platelet counts in WT and hIL-4R/Iba mice prior to radiation. (B) Platelet counts in WT and hIL-4R/Iba mice before and 5 days after a single dose of TPO (20 μ g/kg body weight) administration by intraperitoneal injection. Kaplan–Meier survival curves after exposure to 8.5 Gy TBI. Log-rank tests confirmed that both hIL-4R/Iba with TPO ($p=0.035$) and without TPO ($p=0.003$) had significantly lower percent survival as compared to the WT group. WT $n = 18$; hIL-4R/Iba without TPO ($n = 8$); hIL-4R/Iba with TPO ($n = 9$).




Figure 2. Platelet–neutrophil/monocyte interactions prior to and following TBI.

Whole blood was collected before 8.5 Gy TBI and at 4 h or 24 h after TBI from WT and hIL-4R/Iba mice by retro-orbital puncture. Platelet–neutrophil/monocyte interactions were determined by measuring the percentage of platelet-positive (CD41⁺) events in the neutrophil (Gr-1⁺/CD115⁻) or monocyte (CD115⁺) population. To compare the difference in platelet associations with neutrophils and monocytes between the WT and hIL-4R/Iba mice before and after TBI, a Student's t-test was performed on mean values. * and ** represent p value <0.01, and <0.001, respectively. WT n = 17 (sham), 5 (TBI); hIL-4R/Iba n = 17 (sham), 5 (TBI).




Figure 3. Activation of leukocytes and monocytes following TBI.

The expression of Mac-1 (CD11b/CD18), a marker of leukocyte activation was measured before and after 8.5 Gy TBI. The mean fluorescence intensity (MFI) of Mac-1 was determined for the neutrophil and monocyte population in WT and hIL-4R/Iba mice. To compare the difference in activation of neutrophils and monocytes between the WT and hIL-4R/Iba mice before and after TBI, a Student's t-test was performed on mean values. * and ** signify p value <0.01, and <0.001, respectively. WT n = 17 (sham), 5 (TBI); hIL-4R/Iba n = 17 (sham), 5 (TBI).




Figure 4. Serum cytokines level following TBI.

Circulating serum cytokine levels at days 0 and 4 after 8.5 Gy TBI in WT and hIL-4R/Ibα mice were tested using a multiplex Luminex assay panel for 23 inflammatory analytes. The cytokine data shown are plotted as the means \pm SEM for $n = 3$ to 5 mice/group and include only those cytokines primarily produced by monocytes. a, b, and c, represent $P(\text{value}) < 0.05$ from sham irradiated WT, sham irradiated hIL-4R/Ibα, and irradiated WT, respectively. WT $n = 5$; hIL-4R/Ibα $n = 5$.




Figure 5. Histomorphometric alterations in the intestine.

Alterations in (A) MSA, (B) villus height, (C) crypt depth, and (D) surviving crypt number were measured in hIL-4R/Iba mice and WT mice 4 days after TBI. a, b, and c, represent $P(\text{value}) < 0.05$ from sham irradiated WT, sham irradiated hIL-4R/Iba, and irradiated WT, respectively. To compare the differences in intestinal histomorphometric alteration between the WT and hIL-4R/Iba mice before and after TBI, a Student's t-test was performed on mean values. Additionally, one way ANOVA was performed to assess the presence of statistically significant differences among four groups followed by Tukey's multiple comparison test. WT $n = 5$; hIL-4R/Iba $n = 5$.




Figure 6. Neutrophil infiltration in the intestine following TBI.

Representative photomicrographs (40× magnification) of MPO immunostaining in samples from sham-irradiated (day 0), 4, and 8 days post-irradiation, and the number of MPO-positive cells in immunostained tissue at different time points in WT (n = 4) and hIL-4/Iba mice (n = 4). To compare the differences in MPO positive cells between the WT and hIL-4R/Iba mice before and after TBI, a Student's t-test was performed on mean values.